Old Web
English
Sign In
Acemap
>
authorDetail
>
R. Scott Harris
R. Scott Harris
Vertex Pharmaceuticals
Medicine
Adverse effect
Cystic fibrosis
Ivacaftor
Internal medicine
3
Papers
42
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Endogenous Carbon Monoxide Production and Diffusing Capacity of the Lung for Carbon Monoxide in Sepsis-Induced Acute Respiratory Distress Syndrome.
2020
Yao-Wen Kuo
R. Scott Harris
Dean R. Hess
Paul B. Dieffenbach
Augustine M. K. Choi
Laura E. Fredenburgh
Tilo Winkler
Show All
Source
Cite
Save
Citations (1)
A phase 3, double-blind, parallel-group study to evaluate the efficacy and safety of tezacaftor in combination with ivacaftor in participants 6 through 11 years of age with cystic fibrosis homozygous for F508del or heterozygous for the F508del-CFTR mutation and a residual function mutation
2020
Journal of Cystic Fibrosis
Jane C. Davies
Isabelle Sermet-Gaudelus
Lutz Naehrlich
R. Scott Harris
Daniel Campbell
Neil Ahluwalia
C. Short
Eric L. Haseltine
Paul Panorchan
C Saunders
Caroline A. Owen
Claire E. Wainwright
Show All
Source
Cite
Save
Citations (15)
A phase 3 study of tezacaftor in combination with ivacaftor in children aged 6 through 11 years with cystic fibrosis
2019
Journal of Cystic Fibrosis
Seth Walker
Patrick A. Flume
John McNamara
Melinda Solomon
Mark A. Chilvers
James Chmiel
R. Scott Harris
Eric L. Haseltine
David Stiles
Chonghua Li
Neil Ahluwalia
Honghong Zhou
Caroline A. Owen
Gregory S. Sawicki
Show All
Source
Cite
Save
Citations (26)
1